

**GENETETHER THERAPEUTICS INC.**  
**(the "Company")**

**NOTICE OF CHANGE OF AUDITOR**

**To: Horne LLP**  
**And to: Dale Matheson Carr-Labonte ("DMCL") LLP**

In accordance with National Instrument 51-102 Continuous Disclosure Obligations ("**NI 51-102**"), the Company hereby provides notice as follows:

1. The Company received the resignation of Horne LLP effective as of October 20, 2023;
2. On October 20, 2023, the Company appointed DMCL LLP as its auditor to fill the vacancy created by the resignation of Horne LLP, and to hold such position until the close of the next annual meeting of shareholders of the Company; and
3. The resignation of Horne LLP and the appointment of DMCL LLP was considered and approved by the Company's board of directors.
4. There were no modifications of opinion by Horne LLP in the auditor's reports relating to the Company's financial statements for the "relevant period", as defined in NI 51-102.
5. There are no "reportable events" as defined in NI 51-102.

Dated as of October 20, 2023.

**GENETETHER THERAPEUTICS INC.**

Per:   
\_\_\_\_\_  
Roland Boivin  
Chief Executive Officer